- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.07. | HeartBeam added to Russell Microcap Index | 1 | Seeking Alpha | ||
| 18.06. | HeartBeam, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 20.05. | HeartBeam AI with VCG outperforms cardiologists in detecting arrhythmias | 1 | MassDevice | ||
| 13.05. | Earnings call: HeartBeam reports progress on FDA clearance, Q1 financials | 1 | Investing.com | ||
| 10.05. | Heartbeam Inc reports results for the quarter ended in March - Earnings Summary | 1 | Reuters | ||
| 09.05. | HeartBeam Reports First Quarter 2024 Results | 65 | Business Wire | SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has reported... ► Artikel lesen | |
| 02.05. | HeartBeam, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.04. | HeartBeam AI Combined With Vectorcardiography Delivers Equivalent Performance To 12-lead ECG | 1 | RTTNews | ||
| 09.04. | HeartBeam reports positive results of its AI capabilities for detecting arrhythmias | 1 | Seeking Alpha | ||
| 20.03. | Heartbeam Inc reports results for the quarter ended in December - Earnings Summary | 1 | Reuters | ||
| 20.03. | HeartBeam reports Q4 results | 1 | Seeking Alpha | ||
| 20.03. | Recap: HeartBeam Q4 Earnings | 1 | Benzinga.com | ||
| 20.03. | HeartBeam, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 20.03. | HeartBeam Reports Fourth Quarter and Full Year 2023 Financial Results | 84 | Business Wire | SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has reported... ► Artikel lesen | |
| 19.03. | A Preview Of HeartBeam's Earnings | 1 | Benzinga.com | ||
| 12.03. | What's Going On With Heartbeam (BEAT) Stock? | 3 | Benzinga.com | ||
| 07.03. | HeartBeam secures two new patents for cardiac technology | 1 | Investing.com | ||
| 07.03. | HeartBeam gains on receipt of two US patents for its core cardiac monitoring technology | 1 | Seeking Alpha | ||
| 14.11.23 | HeartBeam Reports Third Quarter 2023 Financial Results | 172 | Business Wire | SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (VECG) platform... ► Artikel lesen | |
| 10.08.23 | HeartBeam Reports Second Quarter 2023 Financial Results | 363 | Business Wire | SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (VECG) platform... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ECKERT & ZIEGLER | 43,360 | +2,12 % | Eckert&Ziegler-Aktie leicht im Minus (43,00 €) | Im deutschen Wertpapierhandel liegt das Wertpapier von Eckert&Ziegler derzeit im Minus. Zuletzt zahlten Investoren für die Aktie 43,00 Euro. Ein Wertverlust in Höhe von 1,54 Euro müssen derzeit die... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 1,266 | -6,22 % | Atossa Therapeutics, Inc.: Atossa Therapeutics Completes Enrollment of 80mg Pharmacokinetic Run-In Cohort in Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen as a Neoadjuvant Treatment for ER+ / HER2- Breast Cancer | SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company") today announced that the 12-patient 80mg pharmacokinetic (PK) run-in cohort of the Phase... ► Artikel lesen | |
| EMEIS | 13,230 | +1,21 % | emeis: Growth in Revenue in First-Half 2024 at €2,772 Million (Up 9.2%) | Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240726471228/en/
emeis (Paris:EMEIS):
Growth in revenue in first-half... ► Artikel lesen | |
| NANO-X IMAGING | 8,590 | +9,29 % | Nano-X Imaging Ltd. - 6-K, Report of foreign issuer | ||
| BUTTERFLY NETWORK | 1,065 | -2,29 % | Butterfly Network Reports First Quarter 2024 Financial Results | BURLINGTON, Mass. & NEW YORK--(BUSINESS WIRE)--Butterfly Network, Inc. (NYSE: BFLY) ("Butterfly" or the "Company"), a digital health company transforming care with handheld, whole-body ultrasound... ► Artikel lesen | |
| GOODRX | 8,850 | +1,26 % | Boehringer Ingelheim and GoodRx announce exclusive patient affordability initiative for Adalimumab-adbm injection, Boehringer's biosimilar to Humira | First biosimilar with an exclusive low cash price on the GoodRx platform RIDGEFIELD, Conn. and SANTA MONICA, Calif., July 18, 2024 /PRNewswire/ -- Boehringer Ingelheim and GoodRx (Nasdaq: GDRX),... ► Artikel lesen | |
| CARMAT | 2,600 | +0,58 % | CARMAT accelerates its sales momentum and reiterates its confidence in its development outlook | 20 implants of the Aeson artificial heart performed in the first half of 2024
Pace of 4 implants per month in the second quarter
Half-year sales at €3.2 million, higher than the... ► Artikel lesen | |
| JOINT CORP | 14,220 | +4,33 % | The Joint Corp. to Host Conference Call on Thursday, August 8th to Discuss Second Quarter 2024 Results | ||
| HYPERFINE | 1,170 | +1,74 % | Hyperfine, Inc. - 8-K, Current Report | ||
| MIMEDX | 7,760 | +0,65 % | MiMedx Group, Inc: MIMEDX Announces Publication Focused on Surgical Applications Using MIMEDX Placental-Based Allografts in Nature - Scientific Reports | ||
| PROGYNY | 29,140 | +1,89 % | Progyny, Inc. Announces Details for Its Second Quarter 2024 Results Report | ||
| PROCEPT BIOROBOTICS | 61,85 | -3,96 % | Procept Biorobotics: Point72 Europe London LLP hat 123800 Aktien dazugekauft! | Medizintechnik-Unternehmen mit 58%-Halbjahresrallye bei Procept Biorobotics (PRCT) Immer noch rote Zahlen, aber viel Potenzial! Procept Biorobotics (PRCT) - ISIN US74276L1052 Rückblick: Das Medizintechnik-Unternehmen... ► Artikel lesen | |
| OUTSET MEDICAL | 3,740 | +0,81 % | Outset Medical Reports First Quarter 2024 Financial Results | SAN JOSE, Calif.--(BUSINESS WIRE)--Outset Medical, Inc. (Nasdaq: OM) ("Outset" or the "Company"), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity... ► Artikel lesen | |
| BIOMERICA | 0,351 | +0,40 % | Biomerica, Inc.: Biomerica Announces inFoods IBS Pilot Launch with Prominent 1,100 Member Physician Group Commencing June 2024 | With IBS affecting 10 to 15% of the global population, the associated $21 billion in direct medical costs and absenteeism underscores the urgent need of innovative solutions. Recognized as the 7th... ► Artikel lesen | |
| ATRICURE | 22,120 | -5,99 % | AtriCure (ATRC) Gains China Approval for AtriClip LAA System |
Das Unternehmen HEARTBEAM INC kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 2,620 Euro und damit -1,13 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HEARTBEAM INC finden Sie auf Wallstreet Online.
